Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-14 11:53 am Sale |
2022-12-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX |
BIOTECHNOLOGY VALUE FUND L P | 1,451,197 2.100% |
-3,480,682 (-70.58%) |
Filing History |
| 2023-02-14 11:50 am Sale |
2022-12-31 | 13G | Calliditas Therapeutics AB (publ) CALT |
BIOTECHNOLOGY VALUE FUND L P | 6,260,311 10.500% |
-1,171,251 (-15.76%) |
Filing History |
| 2023-02-14 11:48 am Purchase |
2022-12-31 | 13G | Calithera Biosciences, Inc. CALA |
BIOTECHNOLOGY VALUE FUND L P | 488,367 9.990% |
488,367 (New Position) |
Filing History |
| 2023-02-14 11:47 am Sale |
2022-12-31 | 13G | Spero Therapeutics, Inc. SPRO |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
-3,411,520 (Position Closed) |
Filing History |
| 2023-02-14 11:45 am Sale |
2022-12-31 | 13G | AN2 Therapeutics, Inc. ANTX |
BIOTECHNOLOGY VALUE FUND L P | 1,563,963 8.100% |
-52,702 (-3.26%) |
Filing History |
| 2023-02-14 11:45 am Purchase |
2022-12-31 | 13G | Sutro Biopharma, Inc. STRO |
BIOTECHNOLOGY VALUE FUND L P | 3,347,946 5.800% |
187,530 (+5.93%) |
Filing History |
| 2023-02-14 11:43 am Purchase |
2022-12-31 | 13G | Viridian Therapeutics, Inc. VRDN |
BIOTECHNOLOGY VALUE FUND L P | 2,302,094 5.600% |
99,779 (+4.53%) |
Filing History |
| 2023-02-14 11:42 am Purchase |
2022-12-31 | 13G | Rein Therapeutics Inc. RNTX |
BIOTECHNOLOGY VALUE FUND L P | 236,835 5.200% |
236,835 (New Position) |
Filing History |
| 2023-02-14 11:40 am Sale |
2022-12-31 | 13G | Aclaris Therapeutics, Inc. ACRS |
BIOTECHNOLOGY VALUE FUND L P | 3,276,543 4.900% |
-591,500 (-15.29%) |
Filing History |
| 2023-02-13 8:20 pm Sale |
2022-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE |
BIOTECHNOLOGY VALUE FUND L P | 1,271,243 2.000% |
-3,034,297 (-70.47%) |
Filing History |
| 2023-02-13 8:16 pm Purchase |
2022-12-31 | 13G | Verastem, Inc. VSTM |
BIOTECHNOLOGY VALUE FUND L P | 1,674,539 9.990% |
132,359 (+8.58%) |
Filing History |
| 2023-02-13 8:14 pm Purchase |
2022-12-31 | 13G | Pieris Pharmaceuticals, Inc. PIRS |
BIOTECHNOLOGY VALUE FUND L P | 96,176 9.990% |
3,593 (+3.88%) |
Filing History |
| 2023-02-13 8:09 pm Purchase |
2022-12-31 | 13G | Molecular Templates, Inc. MTEM |
BIOTECHNOLOGY VALUE FUND L P | 349,771 9.300% |
124,464 (+55.24%) |
Filing History |
| 2023-02-13 6:22 pm Purchase |
2022-12-31 | 13G | Ovid Therapeutics Inc. OVID |
BIOTECHNOLOGY VALUE FUND L P | 6,851,051 9.700% |
220,000 (+3.32%) |
Filing History |
| 2023-02-13 6:20 pm Purchase |
2022-12-31 | 13G | Lexicon Pharmaceuticals, Inc. LXRX |
BIOTECHNOLOGY VALUE FUND L P | 16,149,179 8.600% |
1,789,179 (+12.46%) |
Filing History |
| 2023-02-13 6:19 pm Sale |
2022-12-31 | 13G | Protagonist Therapeutics, Inc. PTGX |
BIOTECHNOLOGY VALUE FUND L P | 1,250,000 2.500% |
-3,641,945 (-74.45%) |
Filing History |
| 2023-02-13 6:17 pm Purchase |
2022-12-31 | 13G | Kura Oncology, Inc. KURA |
BIOTECHNOLOGY VALUE FUND L P | 3,800,983 5.700% |
253,900 (+7.16%) |
Filing History |
| 2023-02-13 6:14 pm Sale |
2022-12-31 | 13G | iTeos Therapeutics, Inc. ITOS |
BIOTECHNOLOGY VALUE FUND L P | 1,810,835 5.100% |
-118,366 (-6.14%) |
Filing History |
| 2023-02-13 6:13 pm Purchase |
2022-12-31 | 13G | Pyxis Oncology, Inc. PYXS |
BIOTECHNOLOGY VALUE FUND L P | 2,938,851 8.400% |
1,147,500 (+64.06%) |
Filing History |
| 2023-02-13 6:11 pm Purchase |
2022-12-31 | 13G | Ikena Oncology, Inc. IKNA |
BIOTECHNOLOGY VALUE FUND L P | 2,503,071 6.900% |
704,700 (+39.19%) |
Filing History |